Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

First Patient Enrolled in BrainStorm's Phase II ALS Trial

Published: Tuesday, June 10, 2014
Last Updated: Tuesday, June 10, 2014
Bookmark and Share
Patient enrollment in Phase II trial at Massachusetts General Hospital in Boston.

BrainStorm Cell Therapeutics has announced that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital (MGH) in Boston.

BrainStorm’s Phase II trial is a randomized, double-blind, placebo controlled multi-center study designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors ("MSC-NTF" or NurOwn™) in 48 ALS patients.

The trial is also being conducted at the University of Massachusetts Memorial (UMass) Hospital in Worcester, MA and the Mayo Clinic in Rochester, Minnesota.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
Mr. Natanson succeeds Dr. Adrian Harel, who will move into an executive scientific role in the company.
Tuesday, January 29, 2013
BrainStorm Establishes Safety of Repeat Doses of NurOwn in Mice
Pre-clinical study conducted at GLP-compliant Harlan Laboratories.
Friday, January 11, 2013
BrainStorm Announces Clinical Data for Safety and Supporting Efficacy of NurOwn™ Based on Initial Phase I/II Results
Data from patients in ALS Phase I/II human clinical trial treated with NurOwn™ technology do not show any side effects.
Wednesday, January 18, 2012
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
New funding includes a grant from the Israeli government’s Office of the Chief Scientist and private investment.
Monday, September 07, 2009
BrainStorm Cell Therapeutics’ Adult Stem Cell Approach More Relevant than Embryonic Stem Cell Therapies
The Company claims that its adult stem cell therapies provide a safer approach at treating neurodegenerative diseases than competitive therapies that rely on embryonic stem cells.
Thursday, November 29, 2007
BrainStorm Cell Therapeutics Initiates Stem Cell Safety Study in Primates for Parkinson’s Disease
The Company has initiated a safety trial using an animal model of Parkinson’s disease in primates utilizing its adult stem cell technology.
Thursday, February 15, 2007
BrainStorm Targets Treatment of Stroke with its Adult Stem Cell Technology
BrainStorm’s bone marrow stem cell technology can differentiate adult stem cells into astrocyte-like cells.
Friday, August 25, 2006
BrainStorm Advances International Patent Application for Stem Cell Procedure
The patent protects a procedure for inducing bone marrow stem cells to differentiate into astrocytes.
Wednesday, July 12, 2006
Scientific News
Manufactured Stem Cells To Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Naked Mole Rat Exhibits “Extraordinary” Cancer Resistance
Scientists are getting closer to understanding the anti-cancer mechanism of the naked mole rat by making induced pluripotent stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Reclaiming The Immune System's Assault On Tumors
EPFL study shows a way to reclaim corrupted immune cells.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
Cirrhosis-Causing Cells Converted to Healthy Liver Cells in Mice
New approach that repairs liver from within may be more efficient than cell transplants.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!